Can Psychedelics Change the Way We See Our Bodies?

The Body We See Is Not Simply the Body That Exists

Most of us assume that seeing our own body is straightforward.

There is a body.

We look at it.

We perceive what is there.

But eating disorders reveal how incomplete that model can be.

The experience of one's body is shaped not only by visual information, but by emotion, expectation, memory, identity, cultural beliefs and the brain's interpretation of internal bodily signals.

A person can intellectually know what their body looks like and still experience it very differently.

That gap between physical body and experienced body can become extraordinarily powerful.

In conditions such as anorexia nervosa, body-image disturbance may persist even when the person's physical condition becomes medically dangerous.

That makes eating disorders a particularly interesting—and difficult—test for psychedelic medicine.

Psychedelics can temporarily alter:

perception,

self-processing,

emotional salience,

cognitive flexibility,

and the ordinary boundaries of identity.

Could those changes help someone experience their body, food or sense of self differently?

Researchers are beginning to ask.

The answer is still uncertain.

Eating Disorders Are Not One Condition

The term eating disorder includes several different psychiatric conditions.

Among the most recognized are:

anorexia nervosa

bulimia nervosa

and

binge-eating disorder.

They can share features, but they are not interchangeable.

Anorexia nervosa may involve severe restriction of food intake, low body weight, intense fear of weight gain and disturbance in how body weight or shape is experienced.

Bulimia nervosa involves recurrent episodes of binge eating accompanied by compensatory behaviors.

Binge-eating disorder involves recurrent binge-eating episodes without the regular compensatory behaviors characteristic of bulimia.

Their medical risks, psychological features and established treatments differ.

So asking whether “psychedelics treat eating disorders” is already too broad.

Most current psychedelic research has focused on anorexia nervosa.

Why Anorexia Is So Difficult to Treat

Anorexia nervosa is not simply a problem of appetite.

For some people, the illness becomes deeply integrated into identity, routine and perceived control.

The thoughts and behaviors surrounding food and body may become extraordinarily rigid.

Recovery can therefore involve much more than restoring weight.

It may require changes in:

self-perception,

habit,

fear,

body image,

emotional regulation,

motivation,

identity,

and the meaning attached to food and control.

This is one reason researchers have become interested in psilocybin.

Not because psychedelic experiences have been shown to cure anorexia.

But because psilocybin may influence several psychological processes that appear relevant to the disorder.

Why Researchers Became Interested in Psychedelics

Classic psychedelics such as psilocybin act primarily through serotonin 5-HT2A receptors and can produce significant changes in perception, emotion, cognition and sense of self.

Researchers have proposed several reasons these effects might be relevant to eating disorders.

Psilocybin may temporarily influence:

cognitive flexibility

rigid self-referential thinking

emotional processing

body perception

psychological insight

and possibly neuroplasticity.

Some of these ideas remain mechanistic hypotheses rather than established treatment pathways.

A 2025 review examining psychedelics and eating disorders described a plausible biological and psychological rationale, particularly in disorders characterized by cognitive rigidity, while emphasizing that clinical evidence remains early.

The theory is interesting.

The clinical question is whether any of it actually helps patients recover.

The First Psilocybin Study in Anorexia

One of the first modern clinical studies specifically examining psilocybin in anorexia nervosa involved 10 adult women with anorexia or partial remission.

Participants received a single 25 mg dose of synthetic psilocybin with psychological support.

The primary purpose was not to establish efficacy.

It was to determine whether the intervention was feasible, tolerable and sufficiently safe to justify further research.

The treatment was generally tolerated.

No clinically significant changes were observed in ECG findings, vital signs or suicidality during the acute study period, although two participants experienced temporary asymptomatic hypoglycemia.

Participants also described the treatment as acceptable overall.

But with only 10 participants and no control group, the study could not establish that psilocybin effectively treats anorexia.

That distinction is crucial.

The 2026 Imperial College Study

The evidence advanced meaningfully in July 2026.

Researchers at Imperial College London's Centre for Psychedelic Research published a pilot study involving 21 adult women with anorexia nervosa. (Original pilot study, published July 8, 2026)

Participants had lived with the disorder for an average of almost 11 years and received three psilocybin sessions over six weeks—one very low dose followed by two 25 mg doses—alongside talk therapy and treatment as usual.

Researchers observed significant reductions in eating-disorder psychopathology over time.

Average global Eating Disorder Examination scores fell from approximately 3.2 at baseline to 2.0 at three months, with improvement still evident at six months.

Motivation for recovery also improved over follow-up.

But responses varied substantially between participants, and maintenance of improvement varied as well.

The study had no conventional placebo-control group.

That means it cannot tell us how much improvement was attributable specifically to:

psilocybin,

psychological support,

treatment as usual,

expectation,

repeated clinical contact,

or some interaction among them.

The results are encouraging.

They are not definitive.

Safety Is Especially Important Here

The 2026 Imperial study also illustrates why psychedelic research in eating disorders requires unusual caution.

The most commonly reported acute adverse effects included:

headache

nausea

and dizziness.

One participant later experienced two suicide attempts during the period between six and twelve months after treatment. The study reports these as serious adverse events during long-term follow-up.

That does not establish that psilocybin caused the events.

But serious events occurring in a medically and psychiatrically vulnerable population must be reported transparently.

Anorexia nervosa can involve:

cardiovascular abnormalities,

electrolyte disturbances,

metabolic complications,

low blood pressure,

malnutrition,

and significant psychiatric comorbidity.

A psychedelic intervention studied in physically healthy volunteers cannot simply be assumed equally safe in someone with severe anorexia.

A 2024 review devoted specifically to psilocybin safety in anorexia emphasized the need for careful medical screening, cardiovascular assessment and attention to the particular physiological vulnerabilities associated with the disorder.

This is why early “well tolerated” findings should not be translated into:

psilocybin is safe for people with eating disorders.

The evidence is not mature enough for that conclusion.

What Does the Evidence Base Actually Look Like?

A systematic review of psilocybin for eating disorders published in 2025, with a literature search running through July 29, 2024, found only two published clinical reports meeting its inclusion criteria. This was a snapshot of that search period, not a count of every study available today. (Systematic review)

The included reports were:

the small open-label anorexia feasibility study,

and a single case report.

The authors also identified six registered trials then investigating psilocybin in eating-disorder populations.

The 2026 Imperial pilot now adds a larger—and more clinically informative—study.

But the overall field remains small.

That means psychedelic treatment for eating disorders should still be understood as experimental, not established care.

Where the Question Began: Ayahuasca

Before controlled psilocybin trials were underway, some of the earliest published research came from people with eating-disorder histories who had used ayahuasca ceremonially.

A qualitative study interviewed 13 people previously diagnosed with eating disorders.

Participants described experiences they believed had helped them:

reduce eating-disorder thoughts,

process painful memories and emotions,

increase self-love and self-acceptance,

and address what they perceived as deeper psychological roots of the disorder.

Some also described spiritual dimensions to the experience.

These reports are worth taking seriously as lived experience.

But they do not establish ayahuasca as an effective eating-disorder treatment.

There was no randomized control group.

Participants selected themselves into ceremonial use.

Their experiences were recalled retrospectively.

And people who found an experience particularly meaningful may have been especially likely to participate.

Qualitative research can reveal important questions.

It cannot answer all of them.

Can Psychedelics Change Body Image?

This is perhaps the most interesting question in the field.

Body image is not merely visual.

It is an integrated experience involving:

vision,

interoception,

emotion,

memory,

belief,

attention,

and identity.

Psychedelics can alter several of these processes simultaneously.

Someone may temporarily experience:

weaker self-boundaries,

greater emotional openness,

less rigid self-judgment,

a changed relationship to the body,

or a different sense of identity.

In principle, that could allow entrenched body-related beliefs to be experienced differently.

But the crucial phrase is:

in principle.

Researchers have not yet established that a temporary change in self-perception produces reliable, durable improvement in body image or eating behavior.

Perception Is Constructed

This connects eating-disorder research to a broader question in consciousness science.

The brain does not simply photograph the body and present the image neutrally.

It constructs an experience of the body using information from:

the senses,

internal bodily signals,

memory,

expectation,

emotion,

and beliefs.

That is why body perception can change without the body itself changing.

It is also why altered states are scientifically interesting.

If psychedelic drugs temporarily modify how the brain weighs or integrates those signals, a person may experience the same body differently.

But again:

changing perception temporarily is not the same as treating a disorder.

The difference between those two outcomes may be the central challenge.

Cognitive Rigidity and Psychological Flexibility

Another proposed mechanism involves cognitive rigidity.

Anorexia can involve repetitive, inflexible thinking around:

food,

weight,

body shape,

rules,

exercise,

and control.

Psychedelic research across several psychiatric conditions has raised the possibility that psilocybin may temporarily increase psychological flexibility or loosen strongly entrenched patterns of thought.

A 2026 article exploring psilocybin across eating disorders describes this as a possible transdiagnostic therapeutic mechanism, particularly because eating disorders frequently coexist with depression, anxiety and other internalizing conditions.

But we should be careful with the phrase neuroplasticity.

A temporary capacity for change does not determine what the change will be.

The existence of a window does not tell us what passes through it.

That is why psychological treatment remains central to the hypothesis.

Psilocybin Plus Psychotherapy

Researchers are increasingly considering psilocybin not as an isolated drug treatment but as a possible adjunct to established psychotherapy.

A 2026 review specifically examined the rationale for combining psilocybin with cognitive behavioral therapy for eating disorders.

The idea is straightforward:

if psilocybin temporarily reduces rigidity or increases psychological flexibility, structured therapy might help direct that period toward clinically relevant learning and behavior change.

This is theoretically attractive.

It remains largely unproven.

The same question appears repeatedly across psychedelic medicine:

Does the drug create the change—or does it create conditions in which other forms of change become easier?

Identity May Matter as Much as Body Image

Anorexia can become intertwined with identity.

For some people, the disorder is not experienced simply as:

something I have.

It may become:

something I am.

That creates a particular therapeutic challenge.

Recovery may threaten a system of control, meaning or identity that has developed over years.

Researchers involved in the 2026 Imperial study highlighted improved motivation to recover as one of the more important findings because anorexia can become deeply embedded in a person's sense of self.

This may help explain why a profound altered state could be psychologically relevant.

A temporary weakening of ordinary self-boundaries might allow someone to imagine a version of themselves less organized around the disorder.

That is a compelling hypothesis.

It is not yet an established mechanism.

A Breakthrough Is Not Recovery

Psychedelic narratives often emphasize moments of dramatic insight.

I finally saw myself differently.

I understood where my illness came from.

I felt compassion for my body.

These experiences may be deeply meaningful.

But eating-disorder recovery requires more than insight.

It may involve:

nutritional rehabilitation,

medical monitoring,

psychotherapy,

changing compulsive behaviors,

learning to tolerate distress,

rebuilding relationships with food,

addressing comorbid illness,

and sustaining change when the altered state is long gone.

Someone can have a profound psychedelic experience and still continue struggling with an eating disorder.

That distinction should never be lost.

A breakthrough can be psychologically significant without being sufficient for recovery.

What About Bulimia and Binge-Eating Disorder?

Current psychedelic evidence is considerably thinner for bulimia nervosa and binge-eating disorder than for anorexia.

A 2025 review examining the serotonin hypothesis of eating disorders discusses theoretical reasons serotonergic psychedelics could eventually be relevant across anorexia, bulimia and binge-eating disorder, including potential effects on emotion regulation, reward processing and cognitive flexibility.

But theoretical plausibility is not clinical evidence.

At present, the strongest modern psilocybin work remains concentrated in anorexia nervosa.

That may change.

It hasn't yet.

Adolescents Are an Even More Sensitive Question

Anorexia often begins during adolescence.

That makes the question of psychedelic treatment in younger people almost inevitable.

But adolescents introduce additional ethical, developmental and safety concerns.

A 2026 review examining possible psilocybin-assisted approaches in adolescent anorexia describes the concept as emerging and emphasizes the need for careful attention to developmental stage, consent, family involvement, medical monitoring and treatment structure.

This remains an area for highly controlled research—not extrapolation from adult psychedelic treatment.

What We Know

Eating disorders are serious psychiatric conditions involving complex interactions among biology, behavior, emotion, perception and social context.

The modern psychedelic evidence base is currently strongest—though still preliminary—for psilocybin in anorexia nervosa.

Small early studies suggest psilocybin-assisted approaches can be feasible and tolerated in carefully selected adult participants.

A 2026 pilot involving 21 women with anorexia found significant improvements over time in eating-disorder symptoms and motivation for change, with some improvement persisting during follow-up. The uncontrolled design prevents firm conclusions about efficacy.

Qualitative ayahuasca research suggests some people with eating-disorder histories report profound changes in self-acceptance, emotional processing and their relationship with the disorder.

Theoretical models suggest psychedelic effects on psychological flexibility, self-processing and emotional learning may be relevant to eating disorders.

These hypotheses remain under investigation.

What We Don't Know

We do not know whether psilocybin reliably produces durable recovery from anorexia nervosa.

We do not know how much improvement observed in uncontrolled studies results from the psychedelic drug versus psychotherapy, treatment as usual, expectancy or intensive clinical support.

We do not know whether altered body perception during a psychedelic experience translates into lasting changes in body image.

We do not know whether mystical experiences or ego dissolution are therapeutically important in eating disorders.

We do not know which patients may benefit—or which may face unacceptable risk.

We do not know the optimal dose, number of sessions or psychotherapy model.

We know considerably less about psychedelic treatment of bulimia nervosa and binge-eating disorder.

And we do not yet know whether psychedelic interventions will ultimately improve established eating-disorder treatment or remain an interesting but limited experimental approach.

The Question That Remains

Eating disorders expose something profound about consciousness.

We do not experience our bodies as neutral objects.

We experience them through layers of perception, memory, judgment, emotion and identity.

That means changing the body and changing the experience of the body are not necessarily the same thing.

Psychedelics may temporarily loosen some of the processes that make a particular self-image feel fixed.

Early research suggests that possibility deserves serious investigation.

But a temporary shift in perspective is only the beginning.

Recovery has to survive breakfast.

The mirror.

The difficult day.

The old habits.

The return of fear.

The ordinary world after the extraordinary experience has ended.

So perhaps the most important question is not whether psychedelics can change the way someone sees their body for several hours.

It is:

If the brain can experience the body differently once, what would it take for that new relationship to endure?

Sources & Further Reading

This article draws on peer-reviewed clinical studies, systematic reviews and qualitative research involving psilocybin, ayahuasca and eating disorders.

Initial feasibility study (2023): Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study, Nature Medicine. Ten participants received one 25 mg dose with psychological support; the study assessed safety and feasibility, not established efficacy.

Evidence snapshot (2025): Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials, Eating and Weight Disorders. Its search through July 2024 identified two clinical reports and six registered trials.

Imperial pilot (July 2026): Psilocybin therapy for adult females with anorexia nervosa: pilot study, The British Journal of Psychiatry. This is the source for the 21-participant sample, fixed-order dosing, eating-disorder scores, follow-up and reported serious adverse events. The absence of a parallel control group prevents attributing improvements specifically to psilocybin.

The strongest current clinical evidence concerns early psilocybin studies in adult anorexia nervosa. Evidence for other eating disorders and psychedelic compounds remains substantially more limited.

Editorial Note

The inclusion of a psychedelic compound or eating disorder in this article indicates an area of research—not an established treatment indication.

Subjective experiences involving body acceptance, self-compassion, insight or psychological breakthrough should not be interpreted as evidence of clinical recovery.

Safety Note

Eating disorders can produce serious and potentially life-threatening medical complications. Psychedelic research involving eating-disorder populations requires careful medical and psychiatric screening and monitoring. This article is not intended to encourage self-directed psychedelic use.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment. Anyone experiencing symptoms of an eating disorder should seek evaluation and care from appropriately qualified healthcare professionals.